WallStSmart

IDEXX Laboratories Inc (IDXX)vsThermo Fisher Scientific Inc (TMO)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Thermo Fisher Scientific Inc generates 918% more annual revenue ($46.34B vs $4.55B). IDXX leads profitability with a 25.0% profit margin vs 15.0%. TMO appears more attractively valued with a PEG of 1.80. IDXX earns a higher WallStSmart Score of 63/100 (C+).

IDXX

Buy

63

out of 100

Grade: C+

Growth: 6.7Profit: 10.0Value: 2.7Quality: 7.0
Piotroski: 6/9Altman Z: 5.92

TMO

Buy

60

out of 100

Grade: C+

Growth: 4.7Profit: 7.0Value: 3.3Quality: 6.0
Piotroski: 3/9Altman Z: 2.13
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

IDXXSignificantly Overvalued (-48.7%)

Margin of Safety

-48.7%

Fair Value

$436.26

Current Price

$511.65

$75.39 premium

UndervaluedFair: $436.26Overvalued
TMOSignificantly Overvalued (-88.3%)

Margin of Safety

-88.3%

Fair Value

$345.90

Current Price

$651.45

$305.55 premium

UndervaluedFair: $345.90Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

IDXX4 strengths · Avg: 9.8/10
Return on EquityProfitability
70.7%10/10

Every $100 of equity generates 71 in profit

Operating MarginProfitability
35.0%10/10

Strong operational efficiency at 35.0%

Altman Z-ScoreHealth
5.9210/10

Safe zone — low bankruptcy risk

Profit MarginProfitability
25.0%9/10

Keeps 25 of every $100 in revenue as profit

TMO2 strengths · Avg: 9.0/10
Market CapQuality
$225.48B10/10

Mega-cap, among the largest globally

Free Cash FlowQuality
$1.68B8/10

Generating 1.7B in free cash flow

Areas to Watch

IDXX3 concerns · Avg: 2.7/10
P/E RatioValuation
36.5x4/10

Premium valuation, high expectations priced in

PEG RatioValuation
2.932/10

Expensive relative to growth rate

Price/BookValuation
25.0x2/10

Trading at 25.0x book value

TMO3 concerns · Avg: 3.7/10
PEG RatioValuation
1.804/10

Expensive relative to growth rate

P/E RatioValuation
32.5x4/10

Premium valuation, high expectations priced in

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Comparative Analysis Report

WallStSmart Research

Bull Case : IDXX

The strongest argument for IDXX centers on Return on Equity, Operating Margin, Altman Z-Score. Profitability is solid with margins at 25.0% and operating margin at 35.0%.

Bull Case : TMO

The strongest argument for TMO centers on Market Cap, Free Cash Flow. Revenue growth of 10.5% demonstrates continued momentum.

Bear Case : IDXX

The primary concerns for IDXX are P/E Ratio, PEG Ratio, Price/Book.

Bear Case : TMO

The primary concerns for TMO are PEG Ratio, P/E Ratio, Piotroski F-Score.

Key Dynamics to Monitor

IDXX profiles as a mature stock while TMO is a value play — different risk/reward profiles.

IDXX carries more volatility with a beta of 1.54 — expect wider price swings.

TMO is growing revenue faster at 10.5% — sustainability is the question.

TMO generates stronger free cash flow (1.7B), providing more financial flexibility.

Bottom Line

IDXX scores higher overall (63/100 vs 60/100), backed by strong 25.0% margins. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

IDEXX Laboratories Inc

HEALTHCARE · DIAGNOSTICS & RESEARCH · USA

IDEXX Laboratories, Inc. is an American multinational corporation engaged in the development, manufacture, and distribution of products and services for the companion animal veterinary, livestock and poultry, water testing, and dairy markets.

Thermo Fisher Scientific Inc

HEALTHCARE · DIAGNOSTICS & RESEARCH · USA

Thermo Fisher Scientific is an American provisioner of scientific instrumentation, reagents and consumables, and software and services to healthcare, life science, and other laboratories in academia, government, and industry (including in the biotechnology and pharmaceutical sectors). Based in Waltham, Massachusetts, Thermo Fisher was created in 2006 by the merger of Thermo Electron and Fisher Scientific, to form a company with US$ 9 billion in combined revenues.

Visit Website →

Want to dig deeper into these stocks?